Cargando…

Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction

Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies’ production. Recently, the US Food and Drug Administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Hamdy MA, Abohamad, Samar, Elfishawi, Mohanad, Hegazy, Mohamed Tharwat, Vijaykumar, Kadambari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254654/
https://www.ncbi.nlm.nih.gov/pubmed/30538431
http://dx.doi.org/10.2147/PPA.S147163
_version_ 1783373772597755904
author Ahmed, Hamdy MA
Abohamad, Samar
Elfishawi, Mohanad
Hegazy, Mohamed Tharwat
Vijaykumar, Kadambari
author_facet Ahmed, Hamdy MA
Abohamad, Samar
Elfishawi, Mohanad
Hegazy, Mohamed Tharwat
Vijaykumar, Kadambari
author_sort Ahmed, Hamdy MA
collection PubMed
description Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies’ production. Recently, the US Food and Drug Administration approved subcutaneous belimumab for patients who have received training on using it. Subcutaneous belimumab can be administered using either a prefilled syringe or an auto-injector device. Weekly subcutaneous belimumab seems to be as effective as monthly intravenous belimumab with a similar safety margin. In this article, we reviewed the literature on subcutaneous belimumab focusing on safety and patients’ experiences and satisfaction. Overall, subcutaneous belimumab appears to be preferred over intravenous belimumab for a number of reasons. However, more studies are still required to prove these findings.
format Online
Article
Text
id pubmed-6254654
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62546542018-12-11 Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction Ahmed, Hamdy MA Abohamad, Samar Elfishawi, Mohanad Hegazy, Mohamed Tharwat Vijaykumar, Kadambari Patient Prefer Adherence Review Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies’ production. Recently, the US Food and Drug Administration approved subcutaneous belimumab for patients who have received training on using it. Subcutaneous belimumab can be administered using either a prefilled syringe or an auto-injector device. Weekly subcutaneous belimumab seems to be as effective as monthly intravenous belimumab with a similar safety margin. In this article, we reviewed the literature on subcutaneous belimumab focusing on safety and patients’ experiences and satisfaction. Overall, subcutaneous belimumab appears to be preferred over intravenous belimumab for a number of reasons. However, more studies are still required to prove these findings. Dove Medical Press 2018-11-21 /pmc/articles/PMC6254654/ /pubmed/30538431 http://dx.doi.org/10.2147/PPA.S147163 Text en © 2018 Ahmed et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Ahmed, Hamdy MA
Abohamad, Samar
Elfishawi, Mohanad
Hegazy, Mohamed Tharwat
Vijaykumar, Kadambari
Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
title Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
title_full Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
title_fullStr Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
title_full_unstemmed Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
title_short Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
title_sort subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254654/
https://www.ncbi.nlm.nih.gov/pubmed/30538431
http://dx.doi.org/10.2147/PPA.S147163
work_keys_str_mv AT ahmedhamdyma subcutaneousformulationofbelimumabintreatmentofsystemiclupuserythematosusacriticalreviewwithfocusonsafetyandsatisfaction
AT abohamadsamar subcutaneousformulationofbelimumabintreatmentofsystemiclupuserythematosusacriticalreviewwithfocusonsafetyandsatisfaction
AT elfishawimohanad subcutaneousformulationofbelimumabintreatmentofsystemiclupuserythematosusacriticalreviewwithfocusonsafetyandsatisfaction
AT hegazymohamedtharwat subcutaneousformulationofbelimumabintreatmentofsystemiclupuserythematosusacriticalreviewwithfocusonsafetyandsatisfaction
AT vijaykumarkadambari subcutaneousformulationofbelimumabintreatmentofsystemiclupuserythematosusacriticalreviewwithfocusonsafetyandsatisfaction